THE WOODLANDS, Texas--(BUSINESS WIRE)--On June 15, 2010, Repros Therapeutics Inc. (NasdaqGM:RPRX) received notification from NASDAQ that it has not regained compliance with NASDAQ Listing Rule 5550(a)(2) and, unless the Company appeals NASDAQ’s decision, trading of the Company’s common stock will be suspended and the Company’s securities will be delisted from the NASDAQ Stock Market.
